Insulet to Present at Upcoming Investor Conferences

Rhea-AI Summary

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two key investor conferences in December 2022 and January 2023. The first event is the Nasdaq 47th Investor Conference in London on December 6, 2022, at 6:30 a.m. ET, followed by the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on January 10, 2023, at 1:30 p.m. ET. Live audio webcasts of the presentations can be accessed through Insulet's investor relations website.

Insulet aims to simplify diabetes management with its innovative Omnipod product platform.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at two upcoming investor conferences:

• The Nasdaq 47^th Investor Conference in London on Tuesday, December 6, 2022 at 6:30 a.m. (Eastern Time)
• The J.P. Morgan 41^st Annual Healthcare Conference in San Francisco on Tuesday, January 10, 2023 at 1:30 p.m. (Eastern Time).

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod^® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2022 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005028/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com



Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When is Insulet presenting at the Nasdaq Investor Conference?

Insulet will present at the Nasdaq 47th Investor Conference in London on December 6, 2022, at 6:30 a.m. ET.

What is the date of the J.P. Morgan 41st Annual Healthcare Conference where Insulet will present?

Insulet will present at the J.P. Morgan 41st Annual Healthcare Conference on January 10, 2023, at 1:30 p.m. ET.

How can I listen to the Insulet presentations at the conferences?

Live audio webcasts of Insulet's presentations can be accessed at their investor relations website.

What is Insulet Corporation's stock symbol?

Insulet Corporation's stock symbol is PODD.

What does Insulet's Omnipod product platform do?

Insulet's Omnipod product platform simplifies insulin delivery for people with diabetes through a tubeless, wearable design.